Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.

ABSTRACT:

Objectives

To assess the clinical characteristics and course of patients with mild cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride.

Design

Cohort study.

Setting

The 59 recruiting sites for the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Participants

Outpatients with MCI and AD in ADNI.

Main outcome measures

The AD Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, and Functional Activities Questionnaire (FAQ).

Results

A total of 177 (44.0%) of 402 MCI patients and 159 (84.6%) of 188 mild-AD patients were treated with ChEIs and 11.4% of MCI patients and 45.7% of AD patients with meman

SUBMITTER: Schneider LS 

PROVIDER: S-EPMC3259850 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature